European Antibody Congress

Date: 31 October 2017 - 2 November 2017

Location:
Congress Center Basel
Messeplatz 21
Basel
4058
Switzerland

Website: www.terrapinn.com/conference/european-antibody-congress/index.stm

Email: [email protected]

Telephone: +44 (0)20 7092 1000

DISCOVER. DEVELOP. GET TO MARKET.

The European Antibody Congress is a critical industry gathering that focuses on the discovery, development, commercialisation and marketing of antibody therapeutics and immunotherapies.

Based in the life science hub of Basel, this event looks at commercialising and pushing forward the entire developmental pipelines of these therapies, as well as focusing on the hottest new individual therapeutics.

Here are the highlights you should not miss for the 13th edition:

• “Strategies for Oncology” keynote panel: Executive representatives from big pharma are coming together to discuss strategies to tackle oncology, including a short presentation from each representative on the current 5-10-year strategical plan. Representatives from Roche, GSK, Eli Lilly and Company, MSD and Pfizer will participate.
• The day three keynote session will focus on academic success and world leading research. Four high level academics will each speak about their most recent, ground-breaking work presenting stories and data.
• A new stream, “Moving from Phase III and Beyond” will be focusing on the crucial steps after phase III trials, through regulatory approval, scale up and tech transfer, manufacture and commercialisation. This will give valuable insight on how to move your formats from bench to bedside.

KEY SPEAKERS INCLUDE:

> Roy Baynes,  SVP & Head, Global Clinical Development, Chief Medical Officer, MSD

> Michael Kalos, Chief Scientific Officer, Cancer Immunobiology, Eli Lilly and Co

> Puja Sapra, Executive Director, Pfizer Worldwide Research and Development

> Michael DeRidder, Senior Director, Early pipeline commercial strategy, Oncology, Cell Therapy, GSK

> Sir Gregory Winter, Master of Trintity Cambridge Universiry, Founder and co-Founder, Bicycle Therapeutics

> Andre Choulika, CEO, Cellectis

> Hans G. Klingemann, Vice President, Research & Development, NantKwest

> John Delaney, Executive Director, Amgen Biologics Discovery

> Andreas Plückthun, Professor of Biochemistry, Director, Department of Biochemistry, University of ZurichAndreas Hougaard Laustsen, Postdoctoral Fellow, Tropical Pharmacology Lab, Technical University of Denmark

> Christian Rommel, Global Head of Oncology Discovery, Roche

> Zelig Eshhar, Professor of Chemical and Cellular Immunology, The Weizmann Institute

Map